M Orditura

Summary

Affiliation: Division of Medical Oncology
Country: Italy

Publications

  1. ncbi request reprint Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study
    M Orditura
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara Cattedra di Oncologia Medica, Naples, Italy
    Ann Oncol 17:1529-32. 2006
  2. ncbi request reprint Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)
    F De Vita
    Division of Medical Oncology, Second University, Napoli, Italy
    Ann Oncol 18:1354-8. 2007
  3. ncbi request reprint Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival
    M Orditura
    F Magrassi Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Italy
    Cancer Immunol Immunother 49:530-6. 2000
  4. ncbi request reprint Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator
    F De Vita
    Division of Internal Medicine, F Magrassi Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy
    J Interferon Cytokine Res 21:45-52. 2001
  5. ncbi request reprint Gemcitabine plus epirubicin in advanced pancreatic cancer: a phase II multicenter trial
    G P Ianniello
    Division of Medical Oncology, G Rummo Hospital, Benevento, Italy
    Oncol Rep 8:1111-5. 2001
  6. ncbi request reprint Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis
    Michele Orditura
    Division of Medical Oncology, F Magrassi Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy
    J Interferon Cytokine Res 22:1129-35. 2002
  7. doi request reprint Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials
    M Orditura
    Department of Clinical and Experimental Medicine and Surgery F Magrassi A Lanzara, Second University of Naples School of Medicine, Naples, Italy
    Dis Esophagus 25:130-6. 2012
  8. pmc A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
    F De Vita
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi e A Lanzara, Second University of Naples, Via Pansini 5, Naples 80131, Italy
    Br J Cancer 104:427-32. 2011
  9. ncbi request reprint Neo-adjuvant and adjuvant chemotherapy of gastric cancer
    F De Vita
    Division of Medical Oncology, Surgical Oncology, F Magrassi and A Lanzara, Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy
    Ann Oncol 18:vi120-3. 2007
  10. pmc Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
    E Martinelli
    Dipartimento Medico Chirurgico di Internistica Clinica, Seconda Universita degli Studi di Napoli, Naples, Italy
    Clin Exp Immunol 158:1-9. 2009

Collaborators

Detail Information

Publications23

  1. ncbi request reprint Weekly docetaxel and capecitabine is not effective in the treatment of advanced gastric cancer: a phase II study
    M Orditura
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara Cattedra di Oncologia Medica, Naples, Italy
    Ann Oncol 17:1529-32. 2006
    ..We assessed the clinical activity and the toxicity of weekly docetaxel in combination with capecitabine in untreated patients with advanced gastric cancer...
  2. ncbi request reprint Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study)
    F De Vita
    Division of Medical Oncology, Second University, Napoli, Italy
    Ann Oncol 18:1354-8. 2007
    ..This randomized, multicenter, phase III trial evaluated the efficacy and safety of the combination of epirubicin, leucovorin, 5-fluorouracil and etoposide (ELFE regimen) as adjuvant therapy for radically resected gastric cancer patients...
  3. ncbi request reprint Behaviour of interleukin-2 serum levels in advanced non-small-cell lung cancer patients: relationship with response to therapy and survival
    M Orditura
    F Magrassi Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Italy
    Cancer Immunol Immunother 49:530-6. 2000
    ..In conclusion, determination of pre-treatment IL-2 serum levels was shown to be of independent prognostic utility in patients with advanced NSCLC; therefore, its possible use for prediction of outcome is proposed...
  4. ncbi request reprint Interleukin-6 serum level correlates with survival in advanced gastrointestinal cancer patients but is not an independent prognostic indicator
    F De Vita
    Division of Internal Medicine, F Magrassi Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy
    J Interferon Cytokine Res 21:45-52. 2001
    ..In conclusion, this study showed that IL-6 serum levels were elevated in advanced gastrointestinal cancer patients and correlated with both OS and TTP. However, they were shown not to be an independent prognostic factor...
  5. ncbi request reprint Gemcitabine plus epirubicin in advanced pancreatic cancer: a phase II multicenter trial
    G P Ianniello
    Division of Medical Oncology, G Rummo Hospital, Benevento, Italy
    Oncol Rep 8:1111-5. 2001
    ..In conclusion, the GEM plus EPI regimen represent a feasible approach for improvement of clinical benefit in advanced pancreatic cancer patients, but confirmatory investigations are required...
  6. ncbi request reprint Elevated serum levels of interleukin-8 in advanced non-small cell lung cancer patients: relationship with prognosis
    Michele Orditura
    Division of Medical Oncology, F Magrassi Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy
    J Interferon Cytokine Res 22:1129-35. 2002
    ..In conclusion, this study showed that IL-8 serum levels were elevated in advanced NSCLC patients and correlated with both OS and TTF, but they were shown not to be an independent prognostic factor...
  7. doi request reprint Complete response to preoperative chemoradiation and survival in esophageal cancer: a pooled analysis of three single-institution phase II trials
    M Orditura
    Department of Clinical and Experimental Medicine and Surgery F Magrassi A Lanzara, Second University of Naples School of Medicine, Naples, Italy
    Dis Esophagus 25:130-6. 2012
    ..0157 and P= 0.0212, respectively). In our series, complete responder patients had a significant longer survival probability after treatment when compared to patients with partial response or stable disease...
  8. pmc A multicenter phase II study of induction chemotherapy with FOLFOX-4 and cetuximab followed by radiation and cetuximab in locally advanced oesophageal cancer
    F De Vita
    Division of Medical Oncology, Department of Clinical and Experimental Medicine and Surgery F Magrassi e A Lanzara, Second University of Naples, Via Pansini 5, Naples 80131, Italy
    Br J Cancer 104:427-32. 2011
    ..Preoperative chemoradiotherapy (CRT) improves the survival of patients with oesophageal cancer when compared with surgery alone...
  9. ncbi request reprint Neo-adjuvant and adjuvant chemotherapy of gastric cancer
    F De Vita
    Division of Medical Oncology, Surgical Oncology, F Magrassi and A Lanzara, Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy
    Ann Oncol 18:vi120-3. 2007
    ..On the contrary, neo-adjuvant chemotherapy has shown promising results as suggested by the final results of UK Medical Research Council Adjuvant Gastric Infusional Chemotherapy trial...
  10. pmc Anti-epidermal growth factor receptor monoclonal antibodies in cancer therapy
    E Martinelli
    Dipartimento Medico Chirurgico di Internistica Clinica, Seconda Universita degli Studi di Napoli, Naples, Italy
    Clin Exp Immunol 158:1-9. 2009
    ..In this review, attention is focused on cetuximab and panitumumab, two mAb introduced recently into clinical practice for treatment of metastatic colorectal and head and neck cancer which target the external part of EGFR...
  11. doi request reprint Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target
    F De Vita
    Division of Medical Oncology, F Magrassi and A Lanzara Department of Clinical and Experimental Medicine and Surgery, Second University of Naples School of Medicine, c o II Policlinico, Via S Pansini 5, Naples, Italy
    Cancer Treat Rev 36:S11-5. 2010
    ..Based on these results trastuzumab combined with a cisplatin and fluoropyrimidine regimen appear the new reference treatment for HER-2 positive metastatic gastric cancer...
  12. doi request reprint Serum vascular endothelial growth factor (VEGF) levels correlate with tumor VEGF and p53 overexpression in endocrine positive primary breast cancer
    F Iovino
    Division of Oncological Surgery, Second University of Naples, Naples, Italy
    Cancer Invest 26:250-5. 2008
    ..041) and circulating VEGF levels (p = 0.047). The results confirm that in primary endocrine-positive breast cancer serum VEGF levels are elevated and show a positive relationship with tumor VEGF and p53 overexpression...
  13. ncbi request reprint Chemoradiotherapy as adjuvant treatment of gastric cancer
    M Orditura
    Department of Medical Oncology, F Magrassi and A Lanzara, Second University of Naples School of Medicine, Naple, Italy
    Ann Oncol 18:vi133-5. 2007
    ..However, many questions remain to evaluate; first of all the toxicity of this approach and its efficacy after adequate surgery...
  14. ncbi request reprint Cetuximab, a chimeric human mouse anti-epidermal growth factor receptor monoclonal antibody, in the treatment of human colorectal cancer
    G Galizia
    Division of Surgery, F Magrassi A Lanzara Department of Clinical and Experimental Medicine and Surgery, Medical and Surgical Oncology and Clinical Immunology, Second University of Naples School of Medicine, Naples, Italy
    Oncogene 26:3654-60. 2007
    ..Furthermore, a series of phase III clinical trials are currently evaluating the combination of cetuximab with standard chemotherapy regimens in the first-line treatment chemotherapy-naïve patients with metastatic CRC...
  15. pmc A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients
    F De Vita
    Division of Medical Oncology, F Magrassi and A Lanzara Department of Clinical and Experimental Medicine, Second University of Naples School of Medicine, Naples, Italy
    Br J Cancer 92:1644-9. 2005
    ..FOLFOX-4 is an active and well-tolerated chemotherapy. Response rate (RR), TTP and OS were comparable with those of other oxaliplatin-based regimens, suggesting a role for this combination in gastric cancer...
  16. ncbi request reprint Oxaliplatin and raltitrexed combined with leucovorin-modulated 5-fluorouracil i.v. bolus every two weeks: a dose finding study in advanced previously treated colorectal carcinoma. Southern Italy Cooperative Oncology Group
    P Comella
    Medical Oncology A, National Tumour Institute, Naples, Italy
    Ann Oncol 11:461-8. 2000
    ....
  17. ncbi request reprint Adjuvant chemotherapy of gastric cancer: which regimens?
    F De Vita
    Division of Medical Oncology, F Magrassi and A Lanzara Department of Clinical and Experimental Medicine, Second University of Naples, School of Medicine, Naples, Italy
    Ann Oncol 16:iv102-105. 2005
    ..Therefore, at present the routine use of adjuvant therapy should be regarded as an investigational approach. Improved clinical trial designs with standardized surgical techniques and the incorporation of newer active drugs are needed...
  18. ncbi request reprint Serum interleukin-10 levels as a prognostic factor in advanced non-small cell lung cancer patients
    F De Vita
    Department of Clinical and Experimental Medicine F Magrassi, Second University of Naples School of Medicine, Naples, Italy
    Chest 117:365-73. 2000
    ..To investigate the prognostic significance of interleukin (IL)-10 serum levels in advanced non-small cell lung cancer (NSCLC) patients...
  19. ncbi request reprint Interaction between the epidermal growth factor receptor (EGFR) and the vascular endothelial growth factor (VEGF) pathways: a rational approach for multi-target anticancer therapy
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Naples, Italy
    Ann Oncol 17:vii109-14. 2006
    ..This review focuses on the preclinical rationale of combining targeted agents such as EGFR and VEGF inhibitors in the treatment of cancer and on the clinical trials that have emerged from these studies...
  20. pmc Oxaliplatin plus raltitrexed and leucovorin-modulated 5-fluorouracil i.v. bolus: a salvage regimen for colorectal cancer patients
    P Comella
    Medical Oncology A, National Tumour Institute, Via M Semmola, 80131 Naples, Italy
    Br J Cancer 86:1871-5. 2002
    ....
  21. pmc Phase II study of gefitinib in combination with docetaxel as first-line therapy in metastatic breast cancer
    F Ciardiello
    Cattedra di Oncologia Medica, Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Via S Pansini 5, 80131 Naples, Italy
    Br J Cancer 94:1604-9. 2006
    ..Complete plus partial responses correlated with oestrogen receptor (ER) status, since they occurred in 19 out of 27 (70%) patients with ER-positive tumours as compared to three out of 14 (21%) patients with ER-negative tumours (P=0.01)...
  22. ncbi request reprint Sequence-dependent antiproliferative effects of cytotoxic drugs and epidermal growth factor receptor inhibitors
    M P Morelli
    Dipartimento Medico Chirurgico di Internistica Clinica e Sperimentale F Magrassi e A Lanzara, Seconda Universita degli Studi di Napoli, Napoli, Italy
    Ann Oncol 16:iv61-68. 2005
    ..Preclinical studies have shown potential antitumor efficacy of these agents in combination with chemotherapy or with radiotherapy. However, controversial results have been obtained in different clinical trials...
  23. ncbi request reprint Hypercoagulable state in patients with advanced gastrointestinal cancer: evidence for an acquired resistance to activated protein C
    D De Lucia
    Institute of General Pathology and Oncology, II University of Naples, Italy
    Tumori 83:948-52. 1997
    ..CONCLUSIONS: Our findings show a high prevalence of APC resistance in cancer, compatible with an acquired defect in the APC pathway...